Xconomy: New York Life Sciences 2031: OrbiMeds Sam Isaly on Genomics, Health Reform, and Biotechs Future
Summary
New York Life Sciences 2031: OrbiMed’s Sam Isaly on Genomics, Health Reform, and Biotech’s Future (Page 2 of 2) metastatic melanoma that’s caused by a gene mutation called BRAF.OrbiMed provided venture funding to Complete Genomics (NASDAQ: GNOM), a Mountain View, CA-based company that staged a successful $54 million IPO in late 2010.“It will be positive.” About 10 percent of the Eaton Vance fund’s portfolio is invested in generic drugs—one of the industry segments that will benefit from that boost in demand, he predicts.At New York Life Sciences 2031, Isaly will be joined by Eric Schadt of Pacific Biosciences, Barbara Dalton of Pfizer’s venture arm, and Sam Waksal of Kadmon.Isaly predicts the panel will offer a good mix of business, entrepreneurial thinking, and “something approaching science fiction,” he says.